Top Ottawa, Ontario Biotech Companies (5)
Don't see your company?
Create a company profile
Our purpose is to realize the promise of viral medicines, thereby extending the horizons of human healthcare. We pioneered a new product category of Viral Sensitizers (VSE™) that removes the barriers to manufacturing effective viral medicines at scale. Customized VSE formulations optimize research processes and enhance production. VSEs help bring your treatments to patients on an accelerated timeline.
IOGEN is a global leader in carbon-negative biofuels technology and solutions. We’re fueling the movement to Net Zero with breakthrough technology that expands the supply side of the equation with new feedstocks. We’re meeting the demand side of the equation with plentiful, affordable and sustainable vehicle, marine and jet fuels. And we’re removing carbon from the atmosphere in the process.
Spiderwort Inc. is a tissue engineering company specializing in the development of transformative biomaterials for repairing and regenerating tissues within the human body.
The Stem Cell Network (SCN) is a Canadian not-for-profit that supports stem cell and regenerative medicine research; training the next generation of highly qualified personnel; and knowledge mobilization and transfer of stem cell and regenerative medicine research. From the lab to the clinic, SCN’s goal is to power life-saving therapies and technologies through regenerative medicine research for the benefit of all. Created in 2001, with support from the Government of Canada, the Network has grown from a few dozen labs to more than 270 world-class research groups, supporting over 250 research projects and 30 clinical trials. Since its inception, over 25 biotech companies have been catalyzed or enhanced and more than 7,000 highly qualified personnel have been trained. In 2021, the Government of Canada demonstrated its continuing trust and support in SCN with an investment of $45 million for the 2022–2025 period. In 2023, the Government of Canada announced additional funding for SCN through the Strategic Science Fund that will support SCN to the end of the decade.
Orion is a clinical stage company leveraging a proprietary technology platform to develop next generation therapeutics for effectively targeting G Protein-Coupled Receptors (GPCRs). Orion’s platform enables effectively targeting previously undruggable complex GPCRs. Our pipeline includes 3 next generation therapeutics for cancer including our lead candidate - OB-002 – which is a first-in-class cancer immunotherapy with best-in-class potency.
Work Your Passion. Live Your Purpose.
